Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
Globe Newswire (Tue, 19-May 8:01 AM ET)
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF's Spring Clinical Meetings
Globe Newswire (Thu, 7-May 8:01 AM ET)
Ardelyx Delivers 38% Revenue Growth and Strong Pipeline Momentum in Q1 2026
Market Chameleon (Fri, 1-May 7:50 AM ET)
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 30-Apr 4:01 PM ET)
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF's Spring Clinical Meetings
Globe Newswire (Mon, 27-Apr 8:01 AM ET)
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Globe Newswire (Mon, 20-Apr 8:00 AM ET)
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Globe Newswire (Thu, 16-Apr 8:01 AM ET)
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
Globe Newswire (Wed, 1-Apr 8:01 AM ET)
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Market Chameleon (Thu, 5-Feb 3:43 AM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of June 10, 2026, ARDX stock price climbed to $5.61 with 2,744,391 million shares trading.
ARDX has a beta of 1.87, meaning it tends to be more sensitive to market movements. ARDX has a correlation of 0.13 to the broad based SPY ETF.
ARDX has a market cap of $1.39 billion. This is considered a Small Cap stock.
Last quarter Ardelyx reported $94 million in Revenue and -$.15 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.01.
In the last 3 years, ARDX traded as high as $10.13 and as low as $3.16.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ARDX has outperformed the market in the last year with a return of +49.2%, while the SPY ETF gained +22.2%. However, in the most recent history, ARDX shares have underperformed the stock market with its stock returning -9.1% in the last 3 month period and -10.2% for the last 2 week period, while SPY has returned +7.2% and -3.4%, respectively.
ARDX support price is $5.44 and resistance is $5.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.